ORF Genetics Ltd. is a privately owned company established in 2001. ORF is committed to developing innovative, economically viable and enabling solutions for the production of recombinant proteins in a more efficient, safer manner than other protein expression systems.
ORF has developed the unique expression system Orfeus™, which uses barley grain as a vehicle for recombinant protein production.
Orfeus™ has been found to be particularly effective in expression of growth factors and cytokines. Efforts in expressing growth factors and cytokines in Orfeus™ have resulted in an extensive portfolio of these type of proteins, enabling ORF to launch two distinctive growth factor/cytokine based products in the market. First for the stem cell research market in 2007 and then into the skin care market in 2008. These product lines are now distributed in over 20 countries and are still growing.
Orfeus™ is continuously surprising ORF´s researchers with its abilities to produce various proteins that can be applied in different markets. ORF´s two newest projects are for example based on Orfeus™ ability to produce significant amounts of a new taste-management protein and a group of diverse ice-structuring proteins, that can be applied in diverse industries such as food, pharmaceutical, cell-research and safety of oil-processing.
We founded BIOEFFECT when we discovered a way to bio-engineer a plant-based replica of EGF, a naturally occurring human protein, in barley. This is BIOEFFECT EGF. Used by over 30% of Icelandic women since its launch in 2010, BIOEFFECT continues to astound users, regardless of age, gender, race, or skin color.